My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 112

    1.

    Use of statins and fibrates in hyperlipidemic patients with neuromuscular disorders.

    Leung NM, Ooi TC, McQueen MJ.

    Ann Intern Med. 2000 Mar 7;132(5):418-9. No abstract available. PMID: 10691600 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Risk of adverse events with fibrates.

    Alsheikh-Ali AA, Kuvin JT, Karas RH.

    Am J Cardiol. 2004 Oct 1;94(7):935-8.PMID: 15464682 [PubMed - indexed for MEDLINE]Related articles

    3.

    [Antilipemic agents, hypothyroidism, and rhabdomyolysis]

    Pía Iglesias G, Garrido Sanjuán JA, González González C, Sesma Sánchez P.

    Rev Clin Esp. 2000 Apr;200(4):236-7. Spanish. No abstract available. PMID: 10857417 [PubMed - indexed for MEDLINE]Related articles

    4.

    Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population.

    McClure DL, Valuck RJ, Glanz M, Murphy JR, Hokanson JE.

    J Clin Epidemiol. 2007 Aug;60(8):812-8. Epub 2007 Mar 26.PMID: 17606177 [PubMed - indexed for MEDLINE]Related articles

    5.

    Simvastatin, fenofibrate, and rhabdomyolysis.

    Jacob SS, Jacob S, Williams C, Deeg MA.

    Diabetes Care. 2005 May;28(5):1258. No abstract available. PMID: 15855605 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?

    Langford NJ, Kendall MJ.

    J Clin Pharm Ther. 2001 Dec;26(6):391-5. No abstract available. PMID: 11722675 [PubMed - indexed for MEDLINE]Related articles

    7.

    Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone.

    Jacobson RH, Wang P, Glueck CJ.

    JAMA. 1997 Jan 22-29;277(4):296-7. No abstract available. PMID: 9002485 [PubMed - indexed for MEDLINE]Related articles

    8.

    The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis.

    Koro CE, Sowell MO, Stender M, Qizilbash N.

    Clin Ther. 2008 Mar;30(3):535-42.PMID: 18405791 [PubMed - indexed for MEDLINE]Related articles

    9.

    Fenofibrate monotherapy-induced rhabdomyolysis in a patient with type-2 diabetes.

    Cetinkaya R, Uyanik A, Yildirim R, Bilen Y, Keles M.

    Indian J Med Sci. 2008 Nov;62(11):458-9. No abstract available. PMID: 19265237 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy.

    Górriz JL, Sancho A, Lopez-Martin JM, Alcoy E, Catalán C, Pallardó LM.

    Nephron. 1996;74(2):437-8. No abstract available. PMID: 8893176 [PubMed - indexed for MEDLINE]Related articles

    11.

    Fenofibrate monotherapy induced rhabdomyolysis.

    Barker BJ, Goodenough RR, Falko JM.

    Diabetes Care. 2003 Aug;26(8):2482-3. No abstract available. PMID: 12882895 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Combination drug therapy for combined hyperlipidemia.

    Guyton JR.

    Curr Cardiol Rep. 1999 Sep;1(3):244-50. Review.PMID: 10980849 [PubMed - indexed for MEDLINE]Related articles

    13.

    Statin-fibrate combination therapy.

    Shek A, Ferrill MJ.

    Ann Pharmacother. 2001 Jul-Aug;35(7-8):908-17. Review.PMID: 11485144 [PubMed - indexed for MEDLINE]Related articles

    14.

    Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis.

    Matzno S, Tazuya-Murayama K, Tanaka H, Yasuda S, Mishima M, Uchida T, Nakabayashi T, Matsuyama K.

    J Pharm Pharmacol. 2003 Jun;55(6):795-802.PMID: 12841940 [PubMed - indexed for MEDLINE]Related articles

    15.

    [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease]

    Kłosiewicz-Latoszek L, Respondek W, Białobrzeska-Paluszkiewicz J, Grzybowska B, Jakóbisiak-Ostasz B, Stolarska I.

    Pol Merkur Lekarski. 2003 Jul;15(85):42-6. Polish. PMID: 14593958 [PubMed - indexed for MEDLINE]Related articles

    16.

    Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives.

    Kamaliah MD, Sanjay LD.

    Singapore Med J. 2001 Aug;42(8):368-72.PMID: 11764054 [PubMed - indexed for MEDLINE]Related articles

    17.

    Hypothyroidism is a predisposing factor for fenofibrate-induced rhabdomyolysis--patient report and literature review.

    Satarasinghe RL, Ramesh R, Riyaaz AA, Gunarathne PA, de Silva AP.

    Drug Metabol Drug Interact. 2007;22(4):279-83. Review.PMID: 18447003 [PubMed - indexed for MEDLINE]Related articles

    18.

    Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma.

    Tong J, Laport G, Lowsky R.

    Bone Marrow Transplant. 2005 Oct;36(8):739-40. No abstract available. PMID: 16086041 [PubMed - indexed for MEDLINE]Related articles

    19.

    Rhabdomyolysis due to bezafibrate in CAPD patients. A role for dihydropyridine drugs?

    Weissgarten J, Zaidenstein R, Fishman S, Dishi V, Michovitz-Koren M, Averbukh Z, Golik A.

    Perit Dial Int. 1999 Mar-Apr;19(2):180-2. No abstract available. PMID: 10357195 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Myotoxicity associated with lipid-lowering drugs.

    Baer AN, Wortmann RL.

    Curr Opin Rheumatol. 2007 Jan;19(1):67-73. Review.PMID: 17143099 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity